查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992137

核酸治療藥物研發生產機構（CDMO）市場：依治療藥物類型、服務類型、治療應用及最終用戶分類－2026-2032年全球市場預測

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核酸療法 CDMO 市場價值將達到 120 億美元，到 2026 年將成長至 133.6 億美元，到 2032 年將達到 261.4 億美元，複合年成長率為 11.76%。

主要市場統計數據
基準年 2025 120億美元
預計年份：2026年 133.6億美元
預測年份 2032 261.4億美元
複合年成長率 (%) 11.76%

在科學和監管需求不斷加快的背景下，CDMO 在推動複雜核酸療法開發方面的戰略作用也在不斷演變。

核酸療法的合約開發與生產（CDMO）產業正進入一個技術快速融合、對研發公司和合約合作夥伴的策略重要性日益凸顯的階段。治療方法、生產平台和監管要求的最新進展，正使CDMO從單純的供應商轉變為對專案進度和臨床可行性具有重大影響的策略合作夥伴。隨著研發人員不斷探索日益複雜的結構，包括修飾寡核苷酸、病毒載體和脂質奈米顆粒製劑，對專業製程知識、嚴格的品管和高度靈活的生產能力的需求也日益成長。

闡明正在改變核酸治療領域研究與開發、生產方法、監管預期和夥伴關係模式的多方面顛覆性因素。

核酸療法正在改變治療模式，推動研發、生產和商業化領域的一系列變革。技術創新正在模式轉移分子設計、生產和測試方式。模組化和連續生產方法正在許多應用中取代傳統的間歇式生產，而數位化製程控制和先進的分析技術作為品質系統和製程理解的基礎，其重要性日益凸顯。這些變革拓寬了合約研發生產機構（CDMO）的能力要求，需要投資於專用設備、即時監控能力和跨領域人才。

本研究評估了 2025 年關稅調整將如何重塑核酸療法整個供應鏈的採購、供應商認證和營運風險管理。

美國在2025年實施和調整關稅，為核酸療法生產的供應和成本計算增加了新的變數。影響進口原料、特殊試劑和某些生產設備的關稅措施迫使製造商和贊助商重新評估籌資策略，並加快認證替代供應商的步伐。因此，採購團隊正在加強對供應商韌性和地理多元化的審查，而生產負責人則在評估維持近岸外包、在岸外包和離岸夥伴關係之間的權衡取捨。

從模式、服務類型、應用程式和最終用戶細分中獲得策略見解，以最佳化產能投資和夥伴關係結構。

從多個細分維度分析需求和產能，可以全面整體情況。從治療藥物類型來看，DNA療法和RNA療法之間的差異對生產流程、分析測試範式和監管環節都產生了顯著影響。 RNA療法通常需要專門的製劑開發技術和低溫運輸管理，而DNA療法在上游和下游純化製程方面則面臨著獨特的挑戰。從服務類型來看，分析測試與品管、生產、包裝和分銷以及製程開發和最佳化之間的相互作用決定了價值的創造點。提供端到端服務的機構可以縮短週期並減少交接環節，但專業領域的專家在高度技術性的任務和方法論開發中仍然發揮著至關重要的作用。

解讀美洲、歐洲、中東和非洲以及亞太地區的區域生態系統、法規結構和能力發展如何影響CDMO的策略定位。

區域趨勢持續影響整個CDMO產業的策略決策，每個區域的需求和產能都受到獨特因素的影響。在美洲，蓬勃發展的生物技術生態系統、創業投資投資以及集中的後期臨床試驗項目，推動了對可擴展生產和嚴格監管合規性的需求。這種環境促使申辦方和生產合作夥伴在臨床到商業化的過渡計畫中密切合作，這要求對符合GMP標準的設施、監管專業知識和供應鏈韌性進行投資。

了解競爭優勢和夥伴關係模式，使 CDMO 能夠透過技術深度、整合服務和以客戶為中心的業務結構實現差異化。

在核酸治療生態系統中，各公司之間的競爭格局日益取決於其在治療模式方面的專業知識深度、整合式服務交付能力，以及透過已建立的監管合作關係降低從臨床試驗到實用化風險的能力。主要企業正透過投資平台技術來提升自身競爭力，這些技術能夠加快製程開發速度、提高產品品質並實現更有效率的規模化生產。產能本身已不再是決定性因素。相反，那些能夠將完善的品質系統、先進的分析技術以及成功的技術轉移經驗相結合的企業，正享有競爭優勢。

高階主管可採取的策略挑戰，以加強夥伴關係、供應鏈韌性、數位化品質和人才隊伍建設，從而開發高可靠性的核酸療法

行業領導者和專案發起人需要採取一系列切實可行的措施，使其營運、夥伴關係和投資計劃與核酸療法開發不斷變化的實際情況相適應。首先，他們應優先考慮共同開發框架，以規範發起人和生產商之間的早期合作，從而加速製程轉移並最大限度地減少下游環節的意外事件。設定共同的里程碑和決策節點有助於明確預期，並減少規模化生產過程中的返工。其次，他們應投資於供應鏈透明度和關鍵原料及合格試劑的雙重採購策略，以因應貿易政策波動和單一來源依賴的風險。儘早對供應商進行資格認證，可以在需要尋找替代供應商時縮短時間。

本文描述了一種混合方法研究設計，該設計結合了對專家的初步訪談、技術檢驗和三角驗證的二級資訊來源，以確保研究結果的可行性和合理性。

本研究採用的調查方法整合了多種證據來源，以確保獲得可靠且可操作的見解。輔助研究包括對科學文獻、監管指導文件、行業白皮書和技術標準進行系統性回顧，以建立技術和監管基準。主要研究則對製造經理、製程科學家、監管專家、採購經理和專案經理進行了結構化訪談，以收集關於營運挑戰、供應商績效和夥伴關係動態的第一手觀點。這些質性資訊輔以技術檢驗工作，包括近期技術轉移案例研究分析、可比性研究和製程放大實例。

本文整合了能力、夥伴關係和供應鏈韌性的策略協調如何決定核酸療法從發現到供應的成功部署。

在科學創新、不斷變化的監管預期和營運需求的驅動下，核酸療法的生產格局瞬息萬變。那些認知到CDMO（合約研發生產機構）夥伴關係的戰略意義，並投資於分析卓越性、適應性生產和彈性供應鏈等綜合能力的企業，將更有能力將科學進展轉化為可靠的臨床和商業供應。關稅導致的供應調整、區域生產能力的重組以及對先進分析的需求等轉型挑戰，雖然會帶來營運上的困難，但也為那些能夠檢驗清晰且經過驗證的、風險可控的規模化生產路徑的供應商創造了新的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核酸治療藥物－依治療藥物類型分類的CDMO市場

  • DNA治療藥物
  • RNA療法

第9章：核酸治療藥物研發生產機構（CDMO）市場：依服務類型分類

  • 分析測試和品管
  • 製造業
  • 包裝/配送
  • 製程開發與最佳化

第10章：核酸治療藥物CDMO市場（依治療應用分類）

  • 遺傳性疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學
  • 罕見疾病

第11章：核酸治療藥物研發生產力機構（CDMO）市場：依最終用戶分類

  • 學術和研究機構
  • 生技公司
  • 製藥公司

第12章：核酸治療藥物研發生產機構（CDMO）市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：核酸治療藥物研發生產機構（CDMO）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：核酸治療藥物研發生產力機構（CDMO）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國核酸治療藥物和CDMO市場

第16章：中國核酸治療藥物CDMO市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market was valued at USD 12.00 billion in 2025 and is projected to grow to USD 13.36 billion in 2026, with a CAGR of 11.76%, reaching USD 26.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.00 billion
Estimated Year [2026] USD 13.36 billion
Forecast Year [2032] USD 26.14 billion
CAGR (%) 11.76%

Framing the evolving strategic role of CDMOs in enabling complex nucleic acid therapeutic development amid accelerating scientific and regulatory demands

The nucleic acid therapeutics contract development and manufacturing landscape has entered a phase defined by rapid technological convergence and elevated strategic importance for both developers and contract partners. Recent advances in therapeutic modalities, manufacturing platforms, and regulatory expectations have elevated CDMOs from service vendors to strategic collaborators that materially influence program timelines and clinical viability. As developers pursue increasingly complex constructs, including modified oligonucleotides, viral vectors, and lipid nanoparticle formulations, demand for specialized process knowledge, stringent quality control, and adaptive manufacturing capacity has intensified.

Consequently, organizations that provide integrated capabilities spanning process development, analytical rigor, and scale-ready manufacturing are being evaluated not only on cost and capacity but also on agility, regulatory track record, and partnership models that de-risk development pathways. Stakeholders must therefore reassess their sourcing strategies, technology roadmaps, and compliance frameworks to reflect an environment where speed-to-clinic and supply continuity are as critical as technical excellence. Moving forward, the interplay between scientific innovation and pragmatic manufacturing constraints will determine which programs advance efficiently and which face protracted development timelines, making it imperative for executives to align commercial strategy with operational realities across the value chain.

Unpacking the multidimensional disruptive forces altering R&D, manufacturing modalities, regulatory expectations, and partnership models across nucleic acid therapeutics

Nucleic acid therapeutics are reshaping therapeutic paradigms, and with that transformation comes a cascade of shifts across R&D, manufacturing, and commercialization. Technological innovation is driving paradigm changes in how molecules are designed, produced, and tested; modular and continuous manufacturing approaches are replacing batch orthodoxy in many applications, while digital process controls and advanced analytics increasingly underpin quality systems and process understanding. These shifts have broadened the competency set required of contract development and manufacturing organizations, requiring investments in specialized equipment, real-time monitoring capabilities, and cross-disciplinary talent.

At the same time, regulatory expectations have matured, emphasizing lifecycle quality management, data integrity, and platform-based comparability. This maturation is influencing project planning and capitalization decisions and is prompting greater early-stage alignment between developers and manufacturers on quality by design principles. Moreover, commercial pressures are altering partnership structures: strategic alliances, risk-sharing arrangements, and capacity reservation models are becoming more common as sponsors seek to secure prioritized throughput and mitigate supply chain risk. Taken together, these transformative shifts mean that CDMOs must evolve beyond transactional relationships to become long-term strategic partners that co-design processes, anticipate regulatory challenges, and scale capabilities in lockstep with evolving modality requirements.

Assessing how tariff adjustments in 2025 have recalibrated sourcing, supplier qualification, and operational risk management across the nucleic acid therapeutics supply chain

The imposition and adjustment of tariffs by the United States in 2025 have introduced new variables into the supply and cost calculus for nucleic acid therapeutics manufacturing. Tariff measures that affect imported raw materials, specialized reagents, and certain manufacturing equipment have prompted manufacturers and sponsors to reassess sourcing strategies and to accelerate efforts to qualify alternative suppliers. As a result, procurement teams have increased scrutiny of supplier resilience and geographic diversification while manufacturing planners evaluate the trade-offs between nearshoring, onshoring, and maintaining offshore partnerships.

In practice, these tariff-driven dynamics have influenced capital allocation decisions and timetable assumptions. Sponsors that previously relied on a global sourcing model for key inputs have initiated dual-sourcing strategies and have elevated buffer management to preserve continuity for critical campaigns. Investments in supplier qualification and audits have increased, as firms seek to validate localized supply chains. Moreover, some organizations have advanced plans for regional capacity expansion to reduce exposure to cross-border cost volatility and mitigate potential lead-time disruptions. Regulatory dossiers and quality control frameworks have had to accommodate the introduction of new supplier-origin materials, requiring targeted comparability studies and additional documentation. While tariffs have not altered the scientific principles behind modality development, they have reshaped operational risk management and have heightened the strategic importance of supply chain transparency, supplier performance metrics, and contractual protections that address cross-border trade risk.

Deriving strategic implications from modality, service type, application, and end-user segmentation to target capability investments and partnership structures

A granular view of the landscape emerges when analyzing demand and capability along multiple segmentation axes. When viewed through the lens of therapeutic type, distinctions between DNA therapeutics and RNA therapeutics materially influence manufacturing workflows, analytical testing paradigms, and regulatory touchpoints; RNA modalities often demand specialized formulation expertise and cold-chain considerations, while DNA-based approaches entail distinct upstream and downstream purification challenges. From the perspective of service type, the interplay between analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization defines where value accrues; organizations that integrate end-to-end services can shorten timelines and reduce handoffs, while niche specialists retain relevance for highly technical tasks and method development.

Considering therapeutic application highlights divergent demand drivers: genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders each present unique payload requirements, dosing regimens, and clinical development risk profiles, which in turn shape manufacturing complexity and demand for tailored assays. Finally, end-user segmentation-academic and research institutes, biotechnology firms, and pharmaceutical companies-reveals differing expectations for flexibility, timelines, and regulatory support; academic partners often require adaptable, lower-volume services focused on method establishment, biotechnology firms prioritize speed and platform scalability for clinical progression, and pharmaceutical companies seek predictable quality systems and capacity for late-stage scale-up. Integrating these segmentation perspectives provides a multidimensional map to prioritize investments, align service offerings, and design partnership models that reflect client-specific needs and modality attributes.

Interpreting how regional ecosystems, regulatory frameworks, and capacity development across the Americas, EMEA, and Asia-Pacific shape CDMO strategic positioning

Regional dynamics continue to influence strategic decisions across the CDMO landscape, with distinct drivers shaping demand and capability in each geography. In the Americas, robust biotech ecosystems, venture capital activity, and a concentration of late-stage clinical programs drive demand for scalable manufacturing and stringent regulatory compliance. This environment fosters closer collaboration between sponsors and manufacturing partners on clinical-to-commercial transition planning and necessitates investments in GMP-capable facilities, regulatory affairs expertise, and supply chain resilience.

In Europe, the Middle East & Africa, evolving regulatory harmonization efforts, a strong translational research base, and growing local biomanufacturing initiatives create opportunities for regional partners to offer specialized capabilities and navigate complex cross-border regulatory landscapes. Sponsors operating in these jurisdictions often balance access to localized scientific talent with the need for interoperable quality systems and regulatory dossiers that align with multiple authorities. The Asia-Pacific region is characterized by rapid capacity expansion, a maturing supplier base for reagents and components, and significant investments by governments and private entities to build domestic manufacturing capabilities. This has encouraged the development of cost-effective manufacturing options as well as opportunities for technology transfer and joint ventures. Across all regions, supply chain transparency, compliance consistency, and the ability to execute complex analytics remain critical selection criteria for sponsors seeking to mitigate geopolitical and operational risks.

Understanding the competitive levers and partnership models that enable CDMOs to differentiate through technical depth, integrated services, and customer-aligned commercial structures

Competitive dynamics among companies serving the nucleic acid therapeutics ecosystem are increasingly defined by depth of modality expertise, integrated service offerings, and the ability to de-risk clinical translation through proven regulatory engagement. Leading providers distinguish themselves by investing in platform technologies that enable faster process development, higher product quality, and streamlined scale-up pathways. Capacity alone no longer differentiates; rather, organizations that combine robust quality systems with advanced analytics and a track record of successful transfers enjoy a competitive edge.

Partnership models are evolving: strategic alliances, co-development agreements, and capacity reservation arrangements are common among organizations seeking to secure long-term pipeline throughput. Investment in talent-particularly in process scientists, analytical chemists, and regulatory specialists-is a critical differentiator, as is the ability to demonstrate successful comparability and validation work across multiple modalities. Mergers and acquisitions continue to be a lever for accessing niche capabilities quickly, but the integration of disparate quality systems and cultures requires deliberate planning. Finally, forward-looking companies prioritize customer-centric commercial models that offer transparency around capacity, pricing mechanisms that reflect value and risk, and collaborative governance structures to resolve program-level challenges efficiently.

Actionable strategic imperatives for executive leaders to strengthen partnerships, supply resilience, digital quality, and talent for reliable nucleic acid therapeutic development

Industry leaders and program sponsors must adopt a set of pragmatic actions to align operations, partnerships, and investment plans with the evolving realities of nucleic acid therapeutic development. First, prioritize co-development frameworks that formalize early-stage collaboration between sponsors and manufacturers to accelerate process transfer and minimize downstream surprises. Establishing joint milestones and decision gates clarifies expectations and reduces rework during scale-up. Second, invest in supply chain visibility and dual-sourcing strategies for critical raw materials and specialized reagents to manage exposure to trade policy shifts and single-source dependencies. Engaging in supplier qualification early will shorten timelines when alternate sources are needed.

Third, accelerate adoption of digital quality management and process analytical technologies to enable real-time monitoring and to support regulatory dossiers that emphasize lifecycle control. These investments reduce batch failure risk and enhance comparability assessments across manufacturing sites. Fourth, align commercial agreements with operational realities by incorporating capacity reservation clauses, risk-sharing provisions, and transparent escalation mechanisms for schedule adjustments. Fifth, build internal capabilities through targeted hiring and training programs that focus on analytics, aseptic processing, and regulatory strategy, while also evaluating strategic acquisitions or partnerships to fill capability gaps rapidly. By implementing these measures, organizations can reduce program risk, preserve development momentum, and create clearer pathways from discovery to commercial supply.

Explaining the mixed-methods research design combining primary expert interviews, technical validation, and triangulated secondary sources to ensure actionable and defensible insights

The underlying research methodology synthesizes multiple evidence streams to ensure robust, actionable insights. Secondary research involved systematic review of scientific literature, regulatory guidance documents, industry white papers, and technical standards to establish baseline technical and regulatory contexts. Primary research consisted of structured interviews with manufacturing leaders, process scientists, regulatory experts, procurement leads, and program managers to capture first-hand perspectives on operational challenges, supplier performance, and partnership dynamics. These qualitative inputs were complemented by technical validation exercises, including case study analyses of recent technology transfers, comparability efforts, and process scale-up examples.

Data triangulation was applied to corroborate themes across sources, ensuring that observed patterns in capacity expansion, quality system investments, and supply chain strategies were not isolated anecdotes. The methodology also incorporated scenario analysis to evaluate the operational implications of shifts such as tariff changes, regional capacity additions, and modality-specific manufacturing complexities. Where appropriate, the research team validated assumptions through follow-up interviews and document reviews to minimize bias. Together, these methods yield a defensible synthesis that balances technical specificity with strategic relevance for decision-makers in development, manufacturing, and commercial organizations.

Synthesizing how strategic alignment of capabilities, partnerships, and supply chain resilience determines successful translation of nucleic acid therapeutics from discovery to supply

The landscape for nucleic acid therapeutics manufacturing is in flux, driven by scientific innovation, evolving regulatory expectations, and shifting operational imperatives. Organizations that recognize the strategic nature of CDMO partnerships and that invest in integrated capabilities-spanning analytical excellence, adaptive manufacturing, and resilient supply chains-will be better positioned to convert scientific advances into reliable clinical and commercial supply. Transitional pains such as tariff-driven supply adjustments, regional capacity realignment, and the need for advanced analytics present operational challenges, but they also create opportunities for providers that can offer clear, validated pathways to de-risked scale-up.

Ultimately, success will favor those who approach manufacturing as a strategic asset rather than a transactional function, establishing collaborative governance, transparent commercial terms, and continuous improvement processes that accelerate program timelines and reduce technical and regulatory risk. By aligning investment priorities with modality-specific demands and by cultivating flexible, high-integrity supply chains, sponsors and providers can create more predictable development trajectories and realize the full potential of nucleic acid therapeutics across diverse therapeutic areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

  • 8.1. DNA Therapeutics
  • 8.2. RNA Therapeutics

9. Nucleic Acid Therapeutics CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing
  • 9.3. Packaging & Distribution
  • 9.4. Process Development & Optimization

10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

  • 10.1. Genetic Disorders
  • 10.2. Infectious Diseases
  • 10.3. Neurological Disorders
  • 10.4. Oncology
  • 10.5. Rare Disorders

11. Nucleic Acid Therapeutics CDMO Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotechnology Firms
  • 11.3. Pharmaceutical Companies

12. Nucleic Acid Therapeutics CDMO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Therapeutics CDMO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Therapeutics CDMO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nucleic Acid Therapeutics CDMO Market

16. China Nucleic Acid Therapeutics CDMO Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AGC Biologics Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Ajinomoto Bio-Pharma Services
  • 17.8. Almac Group Ltd.
  • 17.9. Biomay AG
  • 17.10. BioSpring GmbH
  • 17.11. Catalent, Inc.
  • 17.12. Charles River Laboratories International, Inc.
  • 17.13. CordenPharma International GmbH
  • 17.14. Creative Biogene
  • 17.15. Danaher Corporation
  • 17.16. Eurofins Scientific SE
  • 17.17. Evonik Industries AG
  • 17.18. GenScript Biotech Corporation
  • 17.19. Lonza Group Ltd.
  • 17.20. Polypeptide Group AG
  • 17.21. Recipharm AB
  • 17.22. Rentschler Biopharma SE
  • 17.23. Samsung Biologics
  • 17.24. The Scripps Research Institute
  • 17.25. Touchlight Group
  • 17.26. Univercells Group
  • 17.27. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 99. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 119. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)